KFDA Issues Revised Market Approval Specification for Gemzar
Published: 2005-02-18 06:57:00
Updated: 2005-02-18 06:57:00
The Korea Food and Drug Administration (KFDA) recently issued a revised approval specification for Lilly Korea's Gemzar Inj. 200mg (active ingredient: gemcitabine hydrochloride), a chemotherapy drug for treatment of certain cancer types, including pancreatic cancer.
The revised specification i...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
